Erasca to be valued at up to $1.8 billion

July 13, 2021
Erasca Inc. disclosed that it has set terms of its initial public offering, in which the California-based pre-revenue, clinical-stage precision oncology company could be valued up to $1.84 billion. University of California's researcher, Kevan Shokat PhD., is a lead contributor to Erasca's cancer...

UCSF and PrinterPrezz Collaborate to Produce a Layer of Personal Protection

July 01, 2021
Dr. Alessandro Villa, an Associate Professor at UC San Francisco, and PrinterPrezz, a trailblazer in combining polymer and metal 3D printing, nanotechnologies and surgical expertise to design and manufacture next generation medical devices, today announced a partnership to produce “The Cupola,” a...

The Next Pandemic?

June 30, 2021
Even with powerful vaccines in hand and the coronavirus waning across most of the United States, there’s still an urgent need for drugs to treat COVID-19 — and that could lay the foundation for the next generation of therapies for pandemics, say Bay Area scientists conducting such research. MORE

Sana Biotechnology Shows Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates

June 28, 2021
First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression. Transplanting allogeneic cells into a primate without immune suppression represents a key step toward widespread treatment of disease using...

Akili launches digital campaign for first FDA-approved ADHD video game

June 28, 2021
Akili’s newly launched treatment for ADHD is a prescription—but not a drug. It's a video game. And the company is taking a fittingly digital approach to launching the first-of-its-kind FDA-approved product. MORE

Pionyr And Abcam Extend Partnership To Evaluate TREM2-Expressing Cells In Cancer Patients

June 25, 2021
 Pionyr Immunotherapeutics, Inc., a University of California, San Francisco founded company developing first-in-class antibody therapeutics that increase the body’s anti-tumor immunity and Abcam a global innovator in life science reagents and tools, announced the extension of their collaboration...

Neurona Therapeutics is dashing to the clinic with its cell therapy for epilepsy

June 24, 2021
Neurona Therapeutics unveiled a $41.5 million round on Tuesday morning, bringing the San Francisco-based biotech’s total raise to $135 million. The cash will be used to advance the company’s pipeline, including an upcoming Phase I/IIa for its lead candidate, NRTX-1001, in chronic focal epilepsy.

Next-generation T-cell therapeutics set sights on cancers, autoimmune disorders and more

June 21, 2021
"From my perspective there's no more important system in the body than the immune system, especially T cells," said Jeffrey Bluestone, Ph.D., an emeritus professor of medicine at the UCSF Diabetes Center and CEO of the T cell therapy company Sonoma Biotherapeutics. "T cells are potent, diverse and...

EFFECTOR Therapeutics drops IPO, taking the SPAC path with Locust Walk

June 14, 2021
eFFECTOR Therapeutics, a clinical stage biotech company co-founded by University of California Professor of 
Urology Davide Ruggero, opted out of an IPO to be aquired by Locust Walk Acquisition Corp., a Special Purpose Acquisition Company (SPAC). The deal, anticipated to close in the third quarter...

Alessa Therapeutics Announces IND Clearance to Collaborate with the National Cancer Institute

June 14, 2021
Alessa Therapeutics, Inc., a clinical-stage drug development company founded by University of California, San Francisco professor Dr. Pamela Munster, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for Biolen®. Alessa, in...